Breaking News Instant updates and real-time market news.

BAYRY

Bayer

$0.00

(0.00%)

, BJ

BJ's Wholesale

$25.88

-0.99 (-3.68%)

04:55
09/18/19
09/18
04:55
09/18/19
04:55

Shoptalk to hold a conference

Grocery Shop to be held in Las Vegas on September 15-18.

BAYRY

Bayer

$0.00

(0.00%)

BJ

BJ's Wholesale

$25.88

-0.99 (-3.68%)

BMBOY

Grupo Bimbo

$0.00

(0.00%)

FB

Facebook

$188.13

1.89 (1.01%)

FORR

Forrester

$35.93

-0.31 (-0.86%)

HAIN

Hain Celestial

$22.40

-0.13 (-0.58%)

HSY

Hershey

$152.66

4.64 (3.13%)

IBM

IBM

$142.23

-0.25 (-0.18%)

K

Kellogg

$64.18

0.395 (0.62%)

MDLZ

Mondelez

$54.70

0.64 (1.18%)

NLSN

Nielsen

$22.58

-0.08 (-0.35%)

PG

Procter & Gamble

$121.15

1.4 (1.17%)

PJC

Piper Jaffray

$77.65

-0.27 (-0.35%)

REV

Revlon

$19.66

-0.33 (-1.65%)

SJM

J.M. Smucker

$108.73

1.56 (1.46%)

TGT

Target

$107.27

0.31 (0.29%)

TSN

Tyson Foods

$88.89

2.505 (2.90%)

UL

Unilever; also tag UN

$61.46

1.03 (1.70%)

WMT

Walmart

$116.49

0.97 (0.84%)

  • 19

    Sep

  • 20

    Sep

  • 23

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 25

    Sep

  • 27

    Sep

  • 01

    Oct

  • 08

    Oct

  • 18

    Oct

  • 27

    Oct

  • 29

    Oct

  • 13

    Nov

  • 14

    Nov

BAYRY Bayer
$0.00

(0.00%)

06/04/19
PIPR
06/04/19
NO CHANGE
Target $32
PIPR
Overweight
Piper remains buyer of Arvinas after 'transformative' Bayer alliance
Piper Jaffray analyst Edward Tenthoff views Arvinas' (ARVN) alliance with Bayer (BAYRY) as "transformative." He's a buyer of the stock ahead of the Phase I ARV-110 data in metastatic castrate resistance prostate cancer in the second half of 2019. The analyst estimates Arvinas now holds pro forma cash of $225M to fund operations into the second half of 2021. Tenthoff reiterates an Overweight rating on Bayer with a $32 price target.
07/10/19
WBLR
07/10/19
NO CHANGE
WBLR
Market Perform
Elanco combination with Bayer unlikely for many reasons, says William Blair
Shares of Elanco Animal Health (ELAN) have been unusually volatility over the past two days, William Blair analyst John Kreger tells investors in a research note. On Monday, the FDA approved a generic version of the company's largest product, Rumensin, and yesterday, the media reported speculation that Bayer (BAYRY) has approached Elanco about combining their animal health businesses, the analyst explains. He believes that while a negative development, the Rumensin generic had been expected and thus does not change his modeling assumptions. The Bayer speculation is more surprising but does not seem likely to happen "for a number of reasons," says Kreger. Elanco's largest challenge is bolstering its organic revenue growth, and buying a large company that is growing at a slower pace would only add to this challenge, according the analyst. Further, Elanco has committed to deleverage its balance sheet in the coming year, he adds. And lastly, Kreger believes there could be antitrust challenges from such a large combination. He keeps a Market Perform rating on Elanco shares.
08/26/19
BOFA
08/26/19
DOWNGRADE
Target $30
BOFA
Neutral
BofA/Merrill downgrades Elanco to Neutral on Bayer deal uncertainty
BofA/Merrill analyst Michael Ryskin downgraded Elanco Animal Health (ELAN) to Neutral from Buy with a $30 price target. While the acquisition of Bayer's (BAYRY) Animal Health business could turn out positive in the longer term, there is too much uncertainty in the near-term, including which parts of the portfolio will be divested due to antitrust issues, Ryskin tells investors in a research note. The analyst does not expect answers until nearer to deal close, which is expected in mid-2020.
08/15/19
UBSW
08/15/19
UPGRADE
Target $30
UBSW
Neutral
Elanco upgraded to Neutral from Sell at UBS
UBS analyst Navin Jacob upgraded Elanco Animal Health (ELAN) to Neutral from Sell with a price target of $30, down from $31. While the analyst still see risks to the company's fundamentals from African swine fever and generic Rumensin, he believes the shares are more fairly valued at current levels. Further, some of these headwinds may be offset by companion animal strength, Jacob tells investors in a research note. While concerns of a potential deal with Bayer (BAYRY) have pushed Elanco shares lower, "forecastable" concerns are built in at current levels, says the analyst.
BJ BJ's Wholesale
$25.88

-0.99 (-3.68%)

04/01/19
SBSH
04/01/19
UPGRADE
Target $18
SBSH
Neutral
Bed Bath & Beyond upgraded to Neutral from Sell at Citi
Citi analyst Geoff Small upgraded Bed Bath & Beyond (BBBY) to Neutral from Sell and raised his price target for the shares to $18 from $10 after taking over coverage of the name. Citi transferred coverage of Broadlines & Hardlines Retail names to Small. The analyst assumed coverage with Buy ratings on AutoZone (AZO), BJ's Wholesale (BJ), Home Depot (HD), Lowe's (LOW), O'Reilly Automotive (ORLY) and Walmart (WMT). The U.S. consumer remains on "solid footing" amid low unemployment, rising wages, declining gas prices, manageable levels of debt, and elevated consumer confidence, Small tells investors in a research note. However, he points out that we are in the ninth year of the current economic expansion and "the possibility of a macroeconomic slowdown cannot be ignored." The analyst prefers retailers operating in "defensive sectors that are less susceptible to disruption by online competitors," namely auto parts, broadlines and home improvement retail. Small also assumed Advance Auto Parts (AAP), Best Buy (BBY), Costco (COST) and Office Depot (ODP) with Neutral ratings.
07/18/19
LOOP
07/18/19
NO CHANGE
Target $35
LOOP
Buy
BJ's Wholesale executing strategy in a favorable environment, says Loop Capital
Loop Capital analyst Laura Champine kept her Buy rating and $35 price target on BJ's Wholesale after her latest round of store checks. The analyst believes that the company is executing well on its strategies amid a favorable operating environment for warehouse clubs, but still has an opportunity to improve its value proposition and its range of product categories. Champine is modeling 1.5% comps growth for Q2 against a tough 5% comparison in the corresponding quarter last year.
07/11/19
GSCO
07/11/19
INITIATION
Target $29
GSCO
Buy
BJ's Wholesale initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Kate McShane started BJ's Wholesale with a Buy rating and $29 price target. The company "offers the best attributes within retail," or "value and a treasure hunt experience" with a management team focused on driving both top line and margin growth, says the analyst.
07/15/19
DBAB
07/15/19
INITIATION
Target $29
DBAB
Buy
BJ's Wholesale assumed with a Buy at Deutsche Bank
Deutsche Bank analyst Paul Trussell assumed coverage of BJ's Wholesale with a Buy rating and $29 price target, down from his firm's prior target of $29. The analyst continues to see a shift in dollar share with the rise of e-commerce, fresh, and limited assortment stores, in addition to wholesale clubs and supercenters, at the expense of independents and other regional grocers.
BMBOY Grupo Bimbo
$0.00

(0.00%)

02/26/19
JPMS
02/26/19
UPGRADE
JPMS
Overweight
Grupo Bimbo upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Lucas Ferreira upgraded Grupo Bimbo to Overweight and raised his price target for the shares to MXN46 from MXN 40.
FB Facebook
$188.13

1.89 (1.01%)

09/17/19
SUSQ
09/17/19
UPGRADE
Target $18
SUSQ
Neutral
Susquehanna upgrades Snap to Neutral after positive advertising checks
Susquehanna analyst Shyam Patil upgraded Snap (SNAP) to Neutral from Negative and boosted his price target for the shares to $18 from $12. The stock closed Monday down 24c to $15.76. The analyst's recent advertising channel checks have suggested that Snap's "solid" growth has continued in Q3 with expectations for continued progress in Q4. The checks also show that Facebook's (FB) Instagram Stories "has lowered barriers" for SNAP Stories adoption, Patil tells investors in a research note. The analyst, who also expect Snap's net addition momentum to continue in the second half of 2019, says the stock's valuation is keeping him from getting even more constructive.
09/10/19
GUGG
09/10/19
NO CHANGE
GUGG
Guggenheim sees no evidence of Facebook Dating hurting Match's Tinder
Facebook (FB) Dating is now live in 20 countries and Guggenheim analyst Jake Fuller, in a research note earlier to investors, said he cannot find an example where Match Group's Tinder "took a hit." Further, the analyst points out that Facebook Dating has been live in Canada since November 2018 and that his firm's data shows Tinder daily active users up 45% and downloads up 51% since the launch. Strong" Tinder downloads yield the potential for upside to consensus estimates when Match reports Q3 results, the analyst writes. Despite the launch of Facebook Dating in the U.S., the analyst says his perspective on Match is improving. Nonetheless, Fuller kept a Neutral rating on shares of Match Group, whose stock is down 10c to $77.86 in morning trading.
09/10/19
OPCO
09/10/19
NO CHANGE
OPCO
Perform
Facebook dating survey suggests potential risk for Match Group, says Oppenheimer
Oppenheimer analyst Jason Helfstein surveyed 440 singles to gauge early response to Facebook (FB) Dating, and results highlighted that 40% of respondents were aware of the Facebook Dating product within 48 hours of initial launch in the U.S. Conversion of "aware" users was 15%, and the analyst expects awareness to grow significantly, yielding double digit penetration if the conversion ratio holds. Survey results point to a younger than expected user base, putting Facebook Dating in direct competition with Tinder, he contends. While historical download-data of initial Facebook Dating points to minimal Tinder impact, Helfstein notes that survey results make a compelling argument for near-term headwinds to Match Group (MTCH) shares, coupled with adverse short-term effects from a potential spin of. The analyst has a Perform rating on Match Group's shares.
09/05/19
RHCO
09/05/19
NO CHANGE
RHCO
Buy
Match selloff on Facebook Dating launch a buying opportunity, says SunTrust
SunTrust analyst Youssef Squali views the selloff today in shares of Match Group (MTCH) on Facebook's (FB) launch of Facebook Dating as a buying opportunity. Match's portfolio approach of brands, the "under-penetration" of the category in most markets served, and its leadership position in most markets should allow it to continue to show "healthy growth" with relatively limited impact from Facebook's dating product, Squali tells investors in a research note. Further, he believes "some negative reputational overhang" from the last couple years may prevent mass adoption of Facebook's service. In addition, Facebook's dating feature could potentially attract an older demographic than seen on Match's fastest growing brands such as Tinder and Hinge, says Squali. The analyst maintains a Buy rating on Match Group, whose stock is down 6% to $80.31 in midday trading.
FORR Forrester
$35.93

-0.31 (-0.86%)

02/28/19
MAXM
02/28/19
INITIATION
Target $62
MAXM
Buy
Forrester initiated with a Buy at Maxim
Maxim analyst Allen Klee initiated Forrester with a Buy rating and a price target of $62. The analyst believes that the company is well positioned to accelerate its organic growth through its "multi-year transformation that focuses more on revenue-generating research than cost saving. Klee further notes that nearly two thirds of Forrester's revenue is under annual subscription, adding that its "steady" free cash flows should "provide ample capacity for additional acquisitions."
08/28/19
SIDC
08/28/19
INITIATION
Target $55
SIDC
Buy
Forrester initiated with a Buy at Sidoti
Sidoti started Forrester Research with a Buy rating and $55 price target. The firm believes acquisitions and new product offerings will drive close to 50% annual earnings growth in 2020.
HAIN Hain Celestial
$22.40

-0.13 (-0.58%)

08/28/19
LOOP
08/28/19
NO CHANGE
Target $20
LOOP
Hold
Hain Celestial price target lowered to $20 from $23 at Loop Capital
Loop Capital analyst Andrew Wolf lowered his price target on Hain Celestial to $20 and kept his Hold rating ahead of its Q4 results tomorrow, saying the company's initial FY20 guidance will likely "comport" with the management's previously expressed plans for lower sales but higher sequential EBITDA. The analyst believes this is the right strategy for Hain Celestial longer term, but warns that its initial earnings forecasts will be below the current consensus, as cost deleveraging constrains profitability in the coming year.
08/20/19
JPMS
08/20/19
DOWNGRADE
JPMS
Underweight
Hain Celestial downgraded to Underweight from Neutral at JPMorgan
08/20/19
JPMS
08/20/19
DOWNGRADE
Target $18
JPMS
Underweight
Hain Celestial downgraded to Underweight at JPMorgan, price target cut to $18
JPMorgan analyst Ken Goldman downgraded Hain Celestial downgraded to Underweight from Neutral and lowered his price target to $18 from $23, citing Brexit and currency risk, organic sales risk, the potential for divestitures to raise less cash than expected and valuation. Goldman tells investors in a research note that he is not negative on Hain's strategy, but feels that a number of near-term headwinds may not properly be reflected in the stock price. Additionally, Goldman says he can no longer recommend paying a premium for a company likely to sport margins and returns well below average for a long time.
08/20/19
08/20/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. HP Inc. (HPQ) downgraded to Neutral from Buy at Citi with analyst Jim Suva saying positive PC data points offset mixed Print data points and offer limited positive catalysts. 2. Las Vegas Sands (LVS) downgraded to Hold from Buy at Argus with analyst John Staszak saying the stock should produce "limited growth" over the next 12 months. 3. Hain Celestial (HAIN) and McCormick (MKC) downgraded to Underweight from Neutral at JPMorgan. 4. Itron (ITRI) downgraded Outperform at Credit Suisse with analyst Pavel Molchanov saying having started the year on a "sour" note amid the margin headwinds from components tightness, the stock has shrugged off those issues and is currently at its highest level since early 2018. 5. BP Midstream (BPMP) downgraded to Neutral from Overweight at JPMorgan while Shell Midstream (SHLX) was downgraded to Underweight from Neutral. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
HSY Hershey
$152.66

4.64 (3.13%)

09/12/19
BERN
09/12/19
DOWNGRADE
BERN
Market Perform
Hershey downgraded to Market Perform from Outperform at Bernstein
09/12/19
09/12/19
DOWNGRADE
Target $155

Market Perform
Hershey downgraded to Market Perform on valuation at Bernstein
As previously reported, Bernstein analyst Alexia Howard downgraded Hershey to Market Perform from Outperform, while keeping her $155 price target on the shares. Although the analyst believes that Hershey will continue to enjoy margin improvement and low-single-digit top line growth, she now thinks the benefits of improved input costs and upcoming price increases have largely been recognized by the market.
07/26/19
BMOC
07/26/19
NO CHANGE
Target $133
BMOC
Market Perform
Hershey price target raised to $133 from $108 at BMO Capital
BMO Capital analyst Kenneth Zaslow raised his price target on Hershey to $133 after its second consecutive quarter of earnings outperformance. The analyst also keeps his Market Perform rating, saying that despite the beat, the management kept the upper end of its FY19 outlook on the likelihood of a "muted benefit" from its recent price increase.
07/23/19
WELS
07/23/19
NO CHANGE
Target $130
WELS
Market Perform
Hershey price target raised to $130 from $112 at Wells Fargo
Wells Fargo analyst John Baumgartner raised his price target for Hershey to $130 from $112 ahead of quarterly results. The analyst reiterates a Market Perform rating on the stock as he sees stretched valuations, along with limited upside potential to EPS, as skewing the risk/reward modestly to the downside.
IBM IBM
$142.23

-0.25 (-0.18%)

09/05/19
09/05/19
UPGRADE
Target $12

Outperform
Cloudera upgraded to Outperform from Market Perform at JMP Securities
As previously reported, JMP Securities analyst Patrick Walravens upgraded Cloudera (CLDR) to Outperform from Market Perform with a $12 price target after its Q2 earnings beat and raised FY20 guidance yesterday. The analyst notes that the results were much improved in the latest quarter while also raising his FY20 EPS view to (26c) from (30c). Walravens sees a number of catalysts for Cloudera, including the phased rollout of its Data Platform, new strategic partnerships such as one announced with IBM (IBM) in June, as well as a "new open source licensing and distribution framework that aligns Cloudera's model with industry standards set by Red Hat". The analyst also sees the stock as "quite reasonably valued" at 2.1-times enterprise value to his expected 20201 revenues.
08/06/19
WELS
08/06/19
NO CHANGE
Target $147
WELS
Market Perform
IBM price target raised to $147 from $140 at Wells Fargo
Wells Fargo analyst Ed Caso raised his price target for IBM to $147 from $140 to reflect the recently closed Red Hat acquisition and management's revised 2019 guidance. The analyst reiterates a Market Perform rating on the shares.
08/12/19
JPMS
08/12/19
NO CHANGE
Target $152
JPMS
Neutral
JPMorgan ups IBM target to $152 on favorable view of Red Hat deal
JPMorgan analyst Tien-tsin Huang views IBM's acquisition of Red Hat favorably, saying the asset "should energize" IBM's quest to be the leader in hybrid cloud. The acquisition, while not without risks, could significantly accelerate OpenShift adoption rates, and help Red Hat establish the product as an industry standard in Containerization, Huang tells investors in a research note. He raised his price target for IBM to $152 from $147 but keeps a Neutral rating on the shares. The analyst wants to see proof of integration and execution before getting more constructive on the name.
08/05/19
MSCO
08/05/19
NO CHANGE
Target $170
MSCO
Overweight
IBM guidance with Red Hat in-line with Morgan Stanley expectations
After IBM (IBM) guided calendar year 2019 EPS of "at least" $12.80 when factoring in Red Hat, Morgan Stanley analyst Katy Huberty said this was in-line with her expectation ahead of the event. Following the company's Red Hat presentation, Huberty shifted some of her revenue and EPS forecast into Q4 to reflect the mainframe cycle, but her 2019 estimates for IBM remained otherwise unchanged. Huberty, who thinks Red Hat provides the horizontal platform to bridge the public clouds of AWS (AMZN), Azure (MSFT), GCP (GOOGL), and IBM Cloud, said the "Red Hat acquisition is all about positioning for Chapter 2 of cloud," which will be focused on enterprises' mission critical workloads. Huberty keeps an Overweight rating and $170 price target on IBM shares.
K Kellogg
$64.18

0.395 (0.62%)

08/02/19
GUGG
08/02/19
NO CHANGE
Target $65
GUGG
Neutral
Kellogg price target raised to $65 from $55 at Guggenheim
Guggenheim analyst Laurent Grandet said he was encouraged by Kellogg's improved sales growth momentum in the quarter. He raised his EPS estimates for FY19-FY21 following the report and increased his price target on Kellogg shares to $65 from $55, but keeps a Neutral rating on the stock as he thinks most of the upside is now priced in given the stock's positive reaction.
09/06/19
GSCO
09/06/19
UPGRADE
Target $72
GSCO
Buy
Kellogg upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Jason English upgraded Kellogg to Buy and raised his price target to $72 from $58, saying the stock is the "most compelling value left in snacks" and has a visible path to accelerating its organic sales growth and growing its margins. The analyst cites the recent changes at the company sustaining its faster growth rate, including Kellogg divesting its cookie, fruit snack, pie crust and ice cream cone business as well as benefiting from rising enthusiasm from recent entrants in the "meat alternative" space.
08/01/19
PIVT
08/01/19
NO CHANGE
Target $62
PIVT
Hold
Kellogg reported 'low-quality beat,' says Pivotal Research
Pivotal Research analyst Timothy Ramey said Kellogg reported a "low-quality beat" in Q2 and he doesn't see a reason "to get too bullish yet." While it was encouraging to see organic sales grow, the impacts of its divested businesses will be "quite fierce" though the second of quarter of 2020 and he does not see a path to growth until then, Ramey tells investors. He trimmed his estimates for both 2019 and 2020 and keeps a Hold rating on Kellogg shares with an unchanged price target of $62.
09/06/19
09/06/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Kellogg (K) upgraded to Buy from Neutral at Goldman Sachs with analyst Jason English saying the stock is the "most compelling value left in snacks" and has a visible path to accelerating its organic sales growth and growing its margins. 2. DocuSign (DOCU) upgraded to Outperform from Neutral at Wedbush with analyst Daniel Ives saying the company returned to its "usual beat and raise story," proving last quarter was a "small blip on the radar." 3. Agco (AGCO) upgraded to Buy from Hold at Stifel with analyst Stanley Elliott saying after raveling with management, the analyst is "more encouraged" with the company's margin and market share initiatives. 4. Navistar (NAV) upgraded to Neutral from Sell at Goldman Sachs with analyst Jerry Revich saying he has a positive view of management's "newly cautious" view on 2020 truck demand and he believes freight rates appear to have stabilized. 5. Cheesecake Factory (CAKE) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jon Tower saying the recently announced acquisition of Fox Restaurant Concepts not only transforms the company's growth profile, but also diversifies its real estate footprint and leverages its existing infrastructure, human capital and purchasing scale. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MDLZ Mondelez
$54.70

0.64 (1.18%)

08/07/19
08/07/19
UPGRADE
Target $62

Overweight
Mondelez upgraded to Overweight at Morgan Stanley on topline growth view
As previously reported, Morgan Stanley analyst Dara Mohsenian upgraded Mondelez to Overweight with an unchanged price target of $62. The analyst cites increased confidence in the company's expected sales growth and sees the management's "positive strategy changes" already working, saying the stock should re-rate closer to multinational CPG peers than US-centric food peers.
08/07/19
MSCO
08/07/19
UPGRADE
MSCO
Overweight
Mondelez upgraded to Overweight from Equal Weight at Morgan Stanley
07/31/19
STFL
07/31/19
NO CHANGE
Target $55
STFL
Hold
Mondelez price target raised to $55 from $52 at Stifel
Stifel analyst Christopher Growe said he believes Mondelez shares will respond favorably following the company's strong Q2 report and updated 2019 outlook. Given the upside potential he sees remaining across the second half, Growe raised his price target on Mondelez shares to $55 from $52 and said he maintains a positive bias on the fundamentals. However, since he sees limited upside from the stock's current level, Growe maintains a Hold rating on Mondelez.
07/31/19
BUCK
07/31/19
NO CHANGE
Target $62
BUCK
Buy
Mondelez price target raised to $62 from $57 at Buckingham
Buckingham analyst Eric Larson raised his price target on Mondelez shares to $62 from $57 following the company's "impressive" Q2 sales growth, noting that its organic revenue growth is accelerating and margin visibility is improving. While the stock is still "relatively expensive" on an EV/EBITDA valuation, Larson said there could be conservatism in his sales estimates and he keeps a Buy rating on Mondelez shares.
NLSN Nielsen
$22.58

-0.08 (-0.35%)

06/24/19
SPHN
06/24/19
NO CHANGE
SPHN
LiveRamp acquisition of Data Plus Math reasonably priced, says Stephens
Stephens analyst Brett Huff reiterated an Overweight rating and $59 price target of LiveRamp after the company's acquisition of Data Plus Math. The analyst said the deal was "more reasonably priced than originally thought." Huff added that the acquisition opens up a new $4B total available market in advanced TV measurement market, but he does not see it disrupting Nielsen (NLSN) or comScore (SCOR), but rather making LiveRamp more effective in its existing partnerships with both.
03/28/19
RHCO
03/28/19
NO CHANGE
Target $28
RHCO
Buy
SunTrust not convinced of change in outcome probabilities for Nielsen
SunTrust analyst Matthew Thornton kept his Buy rating and $28 price target on Nielsen, stating that while speculation in New York Post about Blackstone backing out of its bid has hit the price by over 10% afterhours, a separate source reported that the bidding process is "still "very much alive". The analyst states that given the conflicting reports, he is "not convinced that the outcome probabilities have changed that much", adding that the risk-reward on Nielsen is looking "more favorable" with the stock now trading near the "failed transaction valuation".
07/16/19
WELS
07/16/19
NO CHANGE
WELS
Wells says Nielsen restatement could be positive for Monster, tobacco stocks
Wells Fargo analyst Bonnie Herzog noted that Nielsen (NLSN) just announced that it will restate data to address serious issues with its calculation methodology in the convenience store channel related to projections it applied to independent c-stores. The restated data, to be released on August 20, is expected to improve cigarette and energy drink trends and she views this as a positive for tobacco stocks and Monster Beverage (MNST). Publicly traded companies in the tobacco space include Altria Group (MO), British American Tobacco (BTI) and Philip Morris (PM).
08/07/19
LOOP
08/07/19
NO CHANGE
Target $5
LOOP
comScore price target lowered to $5 from $11 at Loop Capital
Loop Capital analyst Alan Gould lowered his price target on comScore (SCOR) to $5 and kept his Hold rating after its below-consensus Q2 results. The analyst maintains his view that the industry "wants a competitor to Nielsen (NLSN) but acknowledges underestimating the difficulty in measuring cross-platform data in a fragmented media universe.
PG Procter & Gamble
$121.15

1.4 (1.17%)

09/11/19
MSCO
09/11/19
NO CHANGE
Target $144
MSCO
Underweight
Clorox valuation unwarranted given widening gap with peers, says Morgan Stanley
Morgan Stanley analyst Dara Mohsenian reiterates his Underweight rating on Clorox (CLX) shares despite the stock's recent underperfomance compared to peers such as Procter & Gamble (PG), Colgate-Palmolive (CL) and Church & Dwight (CHD) as he believes the company's decelerating topline growth, market share losses and lower gross margin expansion make the stock's current valuation compared to peers unwarranted. Though he is not yet revising his estimates, Mohsenian sees risk of downward earnings revisions if scanner trends continue to deteriorate, he tells investors. He maintains a $144 price target on Clorox shares.
08/12/19
MSCO
08/12/19
NO CHANGE
Target $129
MSCO
Overweight
Procter & Gamble EPS growth can outpace peers, says Morgan Stanley
Morgan Stanley analyst Dara Mohsenian reiterated his Overweight rating and $129 price target on Procter & Gamble (PG) following the company's Q4 report, which he said gave him greater confidence in his thesis that the company's market share gains and strong category pricing can continue to drive above-consensus topline growth. Coupled with P&G's outsized gross margin expansion, he expects higher EPS growth than peers, said Mohsenian, who also views the stock's valuation as "attractive."
07/31/19
WELS
07/31/19
NO CHANGE
Target $135
WELS
Outperform
Procter & Gamble price target raised to $135 from $125 at Wells Fargo
Wells Fargo analyst Bonnie Herzog raised her price target for Procter & Gamble to $135 from $125 as she believes "everything clicked into place" for the company in Q4, demonstrating that management's multi-year transformation is "clearly working." The analyst reiterates an Outperform rating on the shares.
07/31/19
FBCO
07/31/19
NO CHANGE
Target $117
FBCO
Neutral
Procter & Gamble price target raised to $117 from $108 at Credit Suisse
Credit Suisse analyst Kaumil Gajrawala raised his price target for Procter & Gamble to $117 from $108 following quarterly results and as he believes the company re-invested the upside back in the business, supporting his view for sustained +MSD% organic growth. The analyst reiterates a Neutral rating on the shares.
PJC Piper Jaffray
$77.65

-0.27 (-0.35%)

REV Revlon
$19.66

-0.33 (-1.65%)

03/20/19
JEFF
03/20/19
NO CHANGE
JEFF
Amazon risk still manageable for beauty retailers, says Jefferies
Jefferies analyst Stephanie Wissink said Amazon's (AMZN) launch of a value priced private label skincare brand, Belei, "came as a bit of a surprise," adding that her sense from contacts inside and outside of the e-commerce company is that the launch is meant to establish a stronger presence, refine a more robust beauty platform and provide data to improve access to national brands. Wissink said it has become increasingly competitive for smaller brands to get into Sephora and Ulta (ULTA) and she expects Amazon to gain access to a growing number of small brands. Wissink points to Ulta's recent strong report as an indicator that with the right, curated assortment, the company is able to protect its position and gain share. Publicly traded skincare and beauty product makers include Estee Lauder (EL), Revlon (REV), Coty (COTY) and e.l.f. Beauty (ELF).
03/05/19
JEFF
03/05/19
NO CHANGE
JEFF
Hold
Revlon sales declines reported to worsen in February, says Jefferies
After reviewing Nielsen data through Feb. 23, Jefferies Stephanie Wissink noted that mass beauty sales decelerated to down 4% in the trailing 4 week period, with all categories stepping lower. By brand, Revlon sales decline of 15% was a deceleration, L'Oreal's (LRCLY) 2% decline was a slight deceleration, e.l.f. Beauty's (ELF) decline of 3% was stable and Coty's (COTY) 4% decline was improved, Wissink tells investors. She keeps Hold rating on all four mass beauty product makers mentioned. In morning trading, shares of Revlon are down $4.95. or 19.4%, to $20.62.
05/14/19
EVER
05/14/19
NO CHANGE
EVER
Shift to online hurting Coty, says Evercore ISI
Evercore ISI analyst Robert Ottenstein says mass beauty products, makeup and fragrances in particular, continue declining, likely reflecting acceleration of the shift to channels not captured in scanner data, namely online and specialty. The analyst believes this shift is most negative for Coty (COTY) and Revlon (REV), as it is tough for drugstore brands to tap into social media. This likely contributes to e.l.f. Beauty's (ELF) turnaround, he contends.
03/05/19
JEFF
03/05/19
NO CHANGE
JEFF
Nielsen data shows worsening trends for Revlon, says Jefferies
SJM J.M. Smucker
$108.73

1.56 (1.46%)

07/22/19
FBCO
07/22/19
NO CHANGE
Target $114
FBCO
Neutral
J.M. Smucker price target lowered to $114 from $120 at Credit Suisse
Credit Suisse analyst Robert Moskow lowered his price target for J.M. Smucker to $114 from $120 to account for his concern that weakness in Smucker's Pet Food will cause the company to miss its revenue growth target. The analyst has a Neutral rating on the shares.
08/28/19
WELS
08/28/19
NO CHANGE
Target $107
WELS
Market Perform
J.M. Smucker price target lowered to $107 from $114 at Wells Fargo
Wells Fargo analyst John Baumgartner lowered his price target for J.M. Smucker to $107 from $114 after the company delivered "big" Q1 revenue and EPS misses, while reducing guidance. The analyst reiterates a Market Perform rating on the shares.
08/28/19
GUGG
08/28/19
NO CHANGE
Target $93
GUGG
Sell
J.M. Smucker price target lowered to $93 from $99 at Guggenheim
Guggenheim analyst Laurent Grandet lowered his price target for J.M. Smucker to $93 from $99 and keeps a Sell rating on the shares. The company's fiscal Q1 results missed expectations and management lowered the company's fiscal 2020 sales and earnings guidance only one quarter into the year, Grandet tells investors in a research note. The analyst continues to think J.M. Smucker will struggle to generate organic growth in the coffee and pet segments.
04/18/19
04/18/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. PepsiCo (PEP) upgraded to Neutral from Sell at Goldman Sachs with analyst Judy Hong citing its "strong" Q1 results that saw organic revenue accelerate to 5% and gross margins top expectations. 2. J.M. Smucker (SJM) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Pamela Kaufman saying she believes the company's reinvestment strategy will drive improved topline momentum across its key segments and should allow the company to return to positive organic growth in FY20. 3. Venator Materials (VNTR) upgraded to Outperform from Sector Perform at RBC Capital with analyst Arun Viswanathan saying he believes that the titanium dioxide "cycle is turning", with destocking activity nearing completion amid improving global demand and pricing. 4. Ecolab (ECL) upgraded to Buy from Neutral at Nomura Instinet with analyst Dan Dolev saying with the problematic energy business soon to be spun-off, Ecolab's "recession resistant qualities should stand out, warranting a significant premium to peers." 5. Qualcomm (QCOM) upgraded to Buy from Hold at DZ Bank. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TGT Target
$107.27

0.31 (0.29%)

08/28/19
TIGR
08/28/19
NO CHANGE
TIGR
Buy
Continued execution by Target driving positive momentum, says Tigress Financial
Tigress Financial analyst Ivan Feinseth kept his Buy rating on Target, saying the company has continued to differentiate itself among retailers with investment in its omni-channel distribution and in offering "unique products". The analyst is also positive on the company's efforts in upgrading its stores and expand its same-day delivery options while experiencing "strong growth" in its in-store traffic as well as its digital channel sales. Feinseth further states that Target's Deal Days event this summer was "very successful".
08/22/19
BMOC
08/22/19
NO CHANGE
Target $105
BMOC
Market Perform
Target price target raised to $105 from $78 at BMO Capital
BMO Capital analyst Kelly Bania raised her price target on Target to $105 after its "strong" top-line momentum in Q2, saying the company is benefiting from its internal drivers of "private label merchandising, designer partnerships, and growing convenience" as well as the external drivers such as weaker mall traffic. The analyst also notes that the company's margin performance was stronger than expected despite the rise in tariff costs, but she still sees valuation expansion potential as limited by the "lack of leverage point on digital fulfillment costs". Bania keeps her Market Perform rating on Target.
08/22/19
FBCO
08/22/19
NO CHANGE
Target $112
FBCO
Outperform
Target price target raised to $112 from $90 at Credit Suisse
Credit Suisse analyst Seth Sigman raised his price target for Target to $112 from $90 as its "stronger" Q2 results continue to support his positive view, centered on its improving competitive position and ability to take share across a number of core categories through an improving omni-channel offering, compelling value proposition and differentiated assortment. The analyst reiterates an Outperform rating on the shares.
08/22/19
08/22/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Target (TGT) upgraded to Buy from Neutral at Citi with analyst Paul Lejuez saying he wants to catch the next 20% move up, which he believes will occur as the company continues to prove it is a "winner" in the current retail landscape. 2. Wayfair (W) upgraded to Buy from Hold at Stifel with analyst Scott Devitt saying the 12% decline in the stock price since the company's posted its Q2 results has created a compelling entry point. 3. Energizer (ENR) upgraded to Buy from Neutral at UBS with analyst Steven Strycula saying the stock has lost 45% of its market cap as a result of the initial integration challenges and higher leverage, but contends that at 9.5-times expected forward EBITDA, he sees the "bear case" being priced in. 4. Etsy (ETSY) upgraded to Buy from Hold at Stifel with analyst Scott Devitt saying the 20% decline in the stock price since the company's last earnings report has made its valuation more compelling. 5. Cerner (CERN) upgraded to Buy from Hold at Argus with analyst Jasper Hellweg saying the company is well positioned for growth having just completed its "self-described 'investment year'." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TSN Tyson Foods
$88.89

2.505 (2.90%)

06/18/19
MZHO
06/18/19
NO CHANGE
MZHO
Mizuho lowers near-term estimates across protein space
Mizuho analyst Jeremy lowered his near-term estimates across the protein space to reflect higher feed costs. Progress reports and persistent flooding in the Midwest suggest "unrecoverable gaps" to projected harvest acreage and a tighter supply in the U.S., Scott tells investors in a research note. Further, a "substantial drop" in soy demand from China and corn demand from other African Swine Fever-impacted regions should help offset the U.S. supply shortfall, adds the analyst. Scott reduced his estimates to reflect the risk of feed cost inflation over the next twelve months, but maintains Buy ratings on Tyson Foods (TSN), Pilgrim's Pride (PPC) and Sanderson Farms (SAFM).
06/21/19
LEHM
06/21/19
NO CHANGE
Target $100
LEHM
Overweight
Tyson Foods price target raised to $100 from $85 at Barclays
Barclays analyst Benjamin Theurer raised his price target for Tyson Foods to $100 from $85 and keeps an Overweight rating on the shares. Diversified animal based protein companies seem set to benefit most from the worsening African Swine Fever situation in China and other countries in Southeast Asia, Theurer tells investors in a research note. Tyson should see a limited impact in 2019 and early 2020, and faces "incrementally more benefits" in the medium to longer term, contends the analyst. He believes industry dynamics are favorable and should allow the company to deliver "strong" growth into next year.
06/26/19
MZHO
06/26/19
NO CHANGE
MZHO
DOJ intervening in poultry case not entirely surprising, says Mizuho
Mizuho analyst Jeremy Scott said it isn't entirely surprising to see the DOJ intervene in the Maplevale civil case against chicken producers given the DOJ's interest in the case previously became apparent in Tyson's (TSN) 10-Q filling in May. Scott said the investigation launch does not necessarily suggest that there is new corroborating evidence, though it does raise the stakes for company legal teams and builds on an already distracting and costly process in the courts that will likely take two years or more to reach a conclusion. Other protein stocks include Hormel (HRL), Pilgrim's Pride (PPC) and Sanderson Farms (SAFM).
08/06/19
MZHO
08/06/19
NO CHANGE
Target $95
MZHO
Buy
Tyson Foods price target raised to $95 from $89 at Mizuho
Mizuho anlayst Jeremy Scott raised his price target for Tyson Foods to $95 from $89 following yesterday's fiscal Q3 results and keeps a Buy rating on the shares. The stock rallied on favorable guidance for both this year and next, including management's outlook that all operating segments would match or beat fiscal 2019 results, including prepared food, Scott tells investors in a research note.
UL Unilever; also tag UN
$61.46

1.03 (1.70%)

05/03/19
FBCO
05/03/19
UPGRADE
FBCO
Outperform
Unilever upgraded to Outperform from Neutral at Credit Suisse
04/09/19
LEHM
04/09/19
INITIATION
LEHM
Underweight
Unilever initiated with an Underweight at Barclays
09/01/19
GSCO
09/01/19
UPGRADE
GSCO
Buy
Unilever upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst John Ennis upgarded Unilever to Buy from Neutral and raised his price target for the shares to 62 euros from 54 euros. The analyst expects the company's growth to pick up in 2020 as India, Brazil and Indonesia start to improve. Further, after underperforming year-to-date, Unilever shares now trade at a 6% price-to-earnings ratio discount on 2020 estimates relative to peers, Ennis tells investors in a research note.
04/25/19
DZBN
04/25/19
DOWNGRADE
DZBN
Hold
Unilever downgraded to Hold from Buy at DZ Bank
WMT Walmart
$116.49

0.97 (0.84%)

09/03/19
MSCO
09/03/19
NO CHANGE
Target $115
MSCO
Overweight
Walmart health clinic plans a 'logical next step,' says Morgan Stanley
Morgan Stanley analyst Simeon Gutman noted that CNBC reported late last week that Walmart is opening a health clinic in Georgia later this month, marking its fourth such clinic. He thinks it makes sense for Walmart, which he notes is the third-largest U.S. pharmacy provider, to play a bigger role in healthcare and sees this is a logical next step given what he views as synergies between retail and healthcare. Sam Walton talked about lowering healthcare costs for consumers as long as 30 years ago, noted Gutman, who thinks standalone health clinics can have positive implications for Walmart's retail business but greater potential consequences for better access to healthcare and lower costs for consumers. He maintains an Overweight rating on Walmart shares.
08/15/19
GDHS
08/15/19
UPGRADE
Target $125
GDHS
Buy
Gordon Haskett upgrades Walmart, calls stock 'a must own' in current environment
Gordon Haskett analyst Chuck Grom said that Walmart is "perceived to be a good port when the waters get choppy," but given the inflection in EBIT and EPS growth from compression to acceleration, he now views the stock as "a must own name." Given his increased conviction following the company's second quarter results, Grom upgraded Walmart to Buy from Accumulate and raised his price target on the stock to $125 from $115. He sees Walmart's acceleration in U.S. same-store sales growth as likely an outlier, rather than the norm in retail, and thinks some of its gross margin shortfall in the quarter was transitory and "self-inflected" due to a greater degree of price actions, Grom noted.
08/16/19
BMOC
08/16/19
NO CHANGE
Target $125
BMOC
Outperform
Walmart price target raised to $125 from $115 at BMO Capital
BMO Capital analyst Kelly Bania raised her price target on Walmart to $125 and kept her Outperform rating, after its "strong" Q2 results, saying the company continues to take market share in the grocery store space while making the right investments in e-commerce to sustain earnings growth in the future. The analyst notes that despite the weather headwinds in seasonal categories, Walmart's EBIT remained on "solid trajectory" and its e-commerce margins expanded for the second consecutive quarter. Bania further cites Walmart "planting the seeds" for future growth with grocery delivery and innovations in healthcare.
09/05/19
MSCO
09/05/19
NO CHANGE
Target $125
MSCO
Overweight
Walmart price target raised to $125 from $115 at Morgan Stanley
Morgan Stanley analyst Simeon Gutman said PhonePe wasn't on investors' radar when Walmart took a majority stake in Flipkart last year, but now the payments processor is coming into focus. Flipkart's PhonePe could be an Indian "Super App" worth from $7B to as much as $20B in a bull case, estimated Gutman, who now believes a sum-of-the-parts analysis is the best way to value Walmart's "disparate segments." He increased his price target on Walmart shares to $125 from $115 and raised his Bull Case valuation on the stock to $165 from $150. Gutman keeps an Overweight rating on Walmart.

TODAY'S FREE FLY STORIES

BHC

Bausch Health

$20.50

-0.12 (-0.58%)

10:25
10/14/19
10/14
10:25
10/14/19
10:25
Options
Bausch Health call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

GNUS

Genius Brands

$0.83

0.06 (7.79%)

10:25
10/14/19
10/14
10:25
10/14/19
10:25
Conference/Events
Genius Brands to host business news update conference call »

Conference call to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

10:25
10/14/19
10/14
10:25
10/14/19
10:25
Conference/Events
UBS technology analyst to hold an analyst/industry conference call »

Technology Analyst…

SDC

SmileDirectClub

$10.56

-0.54 (-4.86%)

10:20
10/14/19
10/14
10:20
10/14/19
10:20
Recommendations
SmileDirectClub analyst commentary  »

SmileDirectClub may or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
10/14/19
10/14
10:17
10/14/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
10/14/19
10/14
10:16
10/14/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLL

Whiting Petroleum

$6.94

-0.5 (-6.72%)

10:15
10/14/19
10/14
10:15
10/14/19
10:15
Options
Whiting Petroleum put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PING

Ping Identity

$16.72

0.25 (1.52%)

, NVST

Envista

$27.55

-0.32 (-1.15%)

10:09
10/14/19
10/14
10:09
10/14/19
10:09
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

PING

Ping Identity

$16.72

0.25 (1.52%)

NVST

Envista

$27.55

-0.32 (-1.15%)

DDOG

Datadog

$36.25

0.58 (1.63%)

BYND

Beyond Meat

$125.99

-5.41 (-4.12%)

BE

Bloom Energy

$3.11

-0.055 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 19

    Nov

  • 04

    Dec

FAST

Fastenal

$35.95

-0.41 (-1.13%)

, AMCX

AMC Networks

$46.77

-1.65 (-3.41%)

10:09
10/14/19
10/14
10:09
10/14/19
10:09
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

FAST

Fastenal

$35.95

-0.41 (-1.13%)

AMCX

AMC Networks

$46.77

-1.65 (-3.41%)

DAL

Delta Air Lines

$52.44

-0.5 (-0.94%)

TOL

Toll Brothers

$39.32

-0.17 (-0.43%)

CGC

Canopy Growth

$18.66

-0.76 (-3.91%)

HEXO

Hexo

$2.38

-0.155 (-6.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 31

    Oct

  • 12

    Nov

  • 12

    Nov

NKE

Nike

$94.70

0.8 (0.85%)

, WDC

Western Digital

$59.86

1.5 (2.57%)

10:09
10/14/19
10/14
10:09
10/14/19
10:09
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

NKE

Nike

$94.70

0.8 (0.85%)

WDC

Western Digital

$59.86

1.5 (2.57%)

VAR

Varian Medical

$112.50

1.72 (1.55%)

XLNX

Xilinx

$96.70

0.52 (0.54%)

HPE

HP Enterprise

$14.77

0.42 (2.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

LK

Luckin Coffee

$18.99

-0.025 (-0.13%)

10:05
10/14/19
10/14
10:05
10/14/19
10:05
Options
Luckin Coffee call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVST

Envista

$27.55

-0.32 (-1.15%)

10:02
10/14/19
10/14
10:02
10/14/19
10:02
Initiation
Envista initiated  »

Envista initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EHTH

eHealth

$53.10

-2.88 (-5.14%)

10:01
10/14/19
10/14
10:01
10/14/19
10:01
Periodicals
eHealth lower following cautious Off Wall Street mention »

Shares of eHealth are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

SAFM

Sanderson Farms

$148.68

-1.2 (-0.80%)

10:00
10/14/19
10/14
10:00
10/14/19
10:00
Conference/Events
Sanderson Farms to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 13

    Nov

RES

RPC, Inc.

$4.55

-0.4 (-8.08%)

10:00
10/14/19
10/14
10:00
10/14/19
10:00
Hot Stocks
RPC, Inc. falls -8.3% »

RPC, Inc. is down -8.3%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 13

    Nov

CRC

California Resources

$8.09

-0.725 (-8.22%)

10:00
10/14/19
10/14
10:00
10/14/19
10:00
Hot Stocks
California Resources falls -9.0% »

California Resources is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

PE

Parsley Energy

$14.79

-2.19 (-12.90%)

10:00
10/14/19
10/14
10:00
10/14/19
10:00
Hot Stocks
Parsley Energy falls -12.8% »

Parsley Energy is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

  • 06

    Nov

UGAZ

VelocityShares 3x Long Natural Gas ETN

$13.86

0.76 (5.80%)

10:00
10/14/19
10/14
10:00
10/14/19
10:00
Hot Stocks
VelocityShares 3x Long Natural Gas ETN rises 5.9% »

VelocityShares 3x Long…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NNA

Navios Acquisition

$10.18

0.64 (6.71%)

10:00
10/14/19
10/14
10:00
10/14/19
10:00
Hot Stocks
Navios Acquisition rises 6.1% »

Navios Acquisition is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DWT

Britannia Bulk

$5.86

0.5 (9.33%)

10:00
10/14/19
10/14
10:00
10/14/19
10:00
Hot Stocks
Britannia Bulk rises 8.9% »

Britannia Bulk is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPE

HP Enterprise

$14.61

0.26 (1.81%)

, PPL

PPL Corp.

$32.12

0.68 (2.16%)

09:55
10/14/19
10/14
09:55
10/14/19
09:55
Options
Early notable gainers among liquid option names on October 14th »

Notable gainers among…

HPE

HP Enterprise

$14.61

0.26 (1.81%)

PPL

PPL Corp.

$32.12

0.68 (2.16%)

WDC

Western Digital

$59.92

1.56 (2.67%)

HPQ

HP Inc.

$16.39

0.16 (0.99%)

VAR

Varian Medical

$112.20

1.42 (1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

  • 23

    Oct

  • 23

    Oct

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

UGAZ

VelocityShares 3x Long Natural Gas ETN

$13.90

0.8 (6.11%)

09:47
10/14/19
10/14
09:47
10/14/19
09:47
Hot Stocks
VelocityShares 3x Long Natural Gas ETN rises 6.1% »

VelocityShares 3x Long…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DWT

Britannia Bulk

$5.71

0.35 (6.53%)

09:47
10/14/19
10/14
09:47
10/14/19
09:47
Hot Stocks
Britannia Bulk rises 6.8% »

Britannia Bulk is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACM

Aecom

$39.82

2.68 (7.22%)

09:47
10/14/19
10/14
09:47
10/14/19
09:47
Hot Stocks
Aecom rises 7.1% »

Aecom is up 7.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

AYTU

Aytu BioScience

$1.21

(0.00%)

09:42
10/14/19
10/14
09:42
10/14/19
09:42
Conference/Events
Aytu BioScience to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.